Generic Name and Formulations:
Gemfibrozil 600mg; scored tabs.
Indications for LOPID:
Type IV and V hyperlipidemias resistant to dietary management, when TG levels are >1000mg/dL and pancreatitis is likely. Reduction in risk of coronary artery disease in certain Type IIb patients with inadequate response to nonpharmacological management and other pharmacologic agents (eg, bile acid sequestrants, nicotinic acid) and have HDL-C levels <35mg/dL, elevated LDL-C and TG. Limitations of use: not indicated for Type I hyperlipoproteinemia with elevated chylomicrons and triglycerides but have normal VLDL. Not indicated for treating patients with low HDL-C as their only lipid abnormality.
1.2g daily in 2 divided doses 30 mins before AM and PM meals.
Hepatic or severe renal dysfunction. Primary biliary cirrhosis. Gallbladder disease. Concomitant simvastatin, repaglinide, or dasabuvir.
Monitor serum lipids and liver function. Discontinue if lipid response is inadequate after 3 months, or if persistent liver abnormalities or gallstones develop. Obtain blood counts periodically during first 12 months. Evaluate any signs/symptoms of muscle pain, tenderness, or weakness; discontinue if myositis is suspected. Patients with baseline creatinine >2mg/dL: consider alternative therapy. Elderly. Pregnancy (Cat.C). Nursing mothers: not recommended.
See Contraindications. Caution with concomitant anticoagulants; reduce warfarin dosage and monitor prothrombin time. May potentiate CYP2C8 substrates (eg, dabrafenib, loperamide, montelukast, paclitaxel, pioglitazone, rosiglitazone) or OATP1B1 substrates (eg, atrasentan, atorvastatin, bosentan, ezetimibe, fluvastatin, glyburide, SN-38 [active metabolite of irinotecan], rosuvastatin, pitavastatin, pravastatin, rifampin, valsartan, olmesartan); may need to reduce dose of these substrates. Myopathy, rhabdomyolysis, and acute renal failure with HMG-CoA reductase inhibitors, colchicine (esp. in elderly or renal dysfunction). Seizure risk with concomitant enzalutamide; may need to reduce dose. Separate dosing of bile acid-binding resins (eg, colestipol) by at least 2hrs.
Dyspepsia, abdominal pain, acute appendicitis, atrial fibrillation, gallbladder disease, cholestatic jaundice, blurred vision, hypesthesia, paresthesias, altered taste, dizziness, somnolence, peripheral neuritis, headache, depression, impotence, decreased libido, myopathy, arthralgia, synovitis, abnormal LFTs, blood dyscrasias, angioedema, rash, cataracts.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Erdafitinib Granted FDA Breakthrough Therapy Designation for Urothelial Carcinoma
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- Nivolumab Plus Ipilimumab Improves Overall Survival, ORR in Renal Cell Carcinoma
- Encorafenib, Binimetinib May Be Effective in BRAF-Mutant Melanoma
- CLL: Venetoclax Plus Rituximab Improves 2-Year PFS
- Confronting Racial Disparities in Prostate Cancer Survival Outcomes
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma